SCHEMBL23728470

SCHEMBL23728470

CCOC(=O)c1cnn2cc(OC)cnc12

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
HPGD P15428 1/20 0.54
KDM4E B2RXH2 4/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
PDE2A O00408 5/20 0.49
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD11B1 P28845 1/20 0.47
PDE4B Q07343 1/20 0.46
GAA P10253 2/20 0.45
IRAK4 Q9NWZ3 2/20 0.43
CSNK1D P48730 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477194 0.85 PDE2A (0.57) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL17781274 0.85 KDM4E (0.57) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728526 0.83 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728550 0.83 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL359148 0.83 HSD11B1 (0.52) ALDH1A1KDM4EPDE2AHSD11B1IRAK4
SCHEMBL23728472 0.82 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL309140 0.82 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL14033767 0.82 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728603 0.80 KDM4E (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL14033079 0.80 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HPGD 3843/4885KDM4E 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.